Nov 10 (Reuters) - Vanda Pharmaceuticals Inc:

ADVERTISEMENT

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia

* Vanda Pharmaceuticals Inc - ‍CHMP re-examined its negative opinion and confirmed refusal of fanaptum MAA​ Source text for Eikon: Further company coverage:

ADVERTISEMENT